Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase

Gynecologic Oncology
Jacek P GrabowskiAndreas du Bois

Abstract

Since almost two decades standard 1st-line chemotherapy for advanced ovarian cancer (AOC) has been a platinum/taxane combination. More recently, this general strategy has been challenged because different types of AOC may not benefit homogenously. Low-grade serous ovarian cancer (LGSOC) is one of the candidates in whom efficacy of standard chemotherapy should be revised. This study is an exploratory case control study of the AGO-metadatabase of 4 randomized phase III trials with first-line platinum combination chemotherapy without any targeted therapy. Patients with advanced FIGO IIIBIV low-grade serous ovarian cancer were included and compared with control cases having high-grade serous AOC. Out of 5114 patients in this AGO database 145 (2.8%) had LGSOC and of those thirty-nine (24.1%) had suboptimal debulking with post-operative residual tumor >1cm, thus being eligible for response evaluation. An objective response was observed in only 10 patients and this 23.1% response rate (RR) was significantly lower compared to 90.1% RR in the control cohort of high-grade serous ovarian cancer (HGSOC) (p<0.001). Both, LGSOC and HGSOC patients who underwent complete cytoreduction had significantly better progression free survival (PFS) an...Continue Reading

References

Apr 12, 2002·The American Journal of Pathology·Gad SingerIe-Ming Shih
Sep 5, 2002·Cancer·Robert E BristowFredrick J Montz
Dec 24, 2002·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Gad SingerRobert J Kurman
Mar 20, 2003·Journal of the National Cancer Institute·Gad SingerIe-Ming Shih
Sep 4, 2003·Journal of the National Cancer Institute·Andreas du BoisUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group
Oct 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chih-Yi HsuIe-Ming Shih
Aug 11, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P HarterJ Pfisterer
Aug 2, 2006·Obstetrics and Gynecology·David M GershensonDiane C Bodurka
Dec 25, 2007·Gynecologic Oncology·Kathleen M SchmelerDavid M Gershenson
Apr 9, 2008·American Journal of Obstetrics and Gynecology·Steven C Plaxe
Oct 22, 2008·Current Oncology Reports·Kathleen M Schmeler, David M Gershenson
Apr 14, 2009·Gynecologic Oncology·David M GershensonJohn J Kavanagh
Aug 25, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas du BoisJalid Sehouli
Mar 13, 2012·Gynecologic Oncology·David M GershensonMichael Deavers
May 28, 2013·Gynecologic Oncology·Ignacio RomeroDavid M Gershenson
Nov 22, 2013·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Stefan KommossFriedrich Kommoss

❮ Previous
Next ❯

Citations

Jun 24, 2016·Gynecologic Oncology·Beyhan AtasevenAndreas du Bois
Jul 30, 2016·Pharmacogenomics·Jennifer McLachlanSusana Banerjee
Oct 25, 2016·Gynecologic Oncology·Anis KaldawySteven A Narod
Feb 22, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David M GershensonCharlotte C Sun
May 13, 2017·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Peter G RoseFadi Adbul-Karim
Feb 9, 2017·Obstetrics and Gynecology·Allison GockleyJ Alejandro Rauh-Hain
Feb 22, 2018·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Luis Felipe SallumSophie Derchain
Oct 12, 2018·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Jonathan S BerekMichael Friedlander
Nov 28, 2018·Journal of Gynecologic Oncology·Giorgio BoganiFrancesco Raspagliesi
Jan 4, 2019·The British Journal of Radiology·Sherif ElsherifPriya Bhosale
May 3, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·N ColomboUNKNOWN ESMO–ESGO Ovarian Cancer Consensus Conference Working Group
May 18, 2019·American Society of Clinical Oncology Educational Book·Bradley J MonkRachel N Grisham
May 18, 2019·American Society of Clinical Oncology Educational Book·Leigh A CantrellLinda R Duska
May 18, 2019·American Society of Clinical Oncology Educational Book·Ainhoa MadariagaAmit M Oza
Dec 19, 2019·The Australian & New Zealand Journal of Obstetrics & Gynaecology·Elizabeth A GouldingPeter Sykes
Jun 17, 2020·Journal of Investigative Medicine High Impact Case Reports·Deeksha MisraSandeep Anand Padala
Jan 15, 2019·Cancer Cell International·Marta Llaurado FernandezMark S Carey
Mar 1, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Luis Felipe SallumSophie Derchain
Aug 14, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas du BoisIgnace Vergote
Apr 28, 2017·Journal of Cancer Research and Clinical Oncology·Miriam RottmannJ Engel
Feb 23, 2019·International Journal of Molecular Sciences·Marco GreppiEmanuela Marcenaro
Jan 31, 2020·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Jacek P GrabowskiJalid Sehouli
May 10, 2020·British Journal of Cancer·Caroline Elizabeth FordKristina Warton
Jan 29, 2020·Current Oncology Reports·Nina PaulyThaïs Baert
Aug 11, 2018·Journal of Cancer Research and Clinical Oncology·Johanna SchiewekSabine Windhorst
Nov 30, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Ioannis A Voutsadakis
Mar 30, 2020·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Claudia MarchettiAnna Fagotti
Aug 14, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David M GershensonIsabelle Ray-Coquard
May 6, 2020·The Oncologist·Parker L Bussies, Matthew Schlumbrecht
May 7, 2019·American Journal of Medical Genetics. Part a·Chiara LeoniGiuseppe Zampino
Nov 1, 2020·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Jacek P GrabowskiJalid Sehouli
Jun 25, 2017·Cancer Research·Dariush EtemadmoghadamUNKNOWN Australian Ovarian Cancer Study Group
May 3, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N ColomboUNKNOWN ESMO-ESGO Ovarian Cancer Consensus Conference Working Group
Feb 20, 2021·Seminars in Cancer Biology·Marco PetrilloVito Chiantera
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N ColomboUNKNOWN ESMO-ESGO Ovarian Cancer Consensus Conference Working Group
May 3, 2021·Gynécologie, Obstétrique, Fertilité & Sénologie·F ZaccariniS Gouy

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.